Pancreatic Cancer Symposium 2017
By the year 2020, pancreatic cancer is projected to be the second leading cause of cancer-related death in the United States. The incidence of pancreatic cancer in Wisconsin is among the highest in the country.
This year, our symposium has been structured to provide a comprehensive overview of the management of patients with pancreatic cancer for clinicians with all levels. Our morning session will focus on the diagnostic workup and staging for newly diagnosed patients and outline stage-specific treatment principles. In our mid-morning session, we will review of the recent proceedings at GI ASCO and discuss novel targets for pancreatic cancer with Dr. Gauri Varadhachary, from the MD Anderson Cancer Center. Finally, our afternoon session will look to the future in pancreatic cancer research, with a focus on utilization of treatment biomarkers and a basic science lecture from Marina Pasca di Magliano, PhD, of the University of Michigan.
CCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Hours of Participation for Allied Health Professionals:
The Medical College of Wisconsin designates this activity for up to 6.0 hours of participation for continuing education for allied health professionals
Please note: a $4.00 processing fee will be assessed for all registrations.
There is a $25 cancellation fee.
This course is complimentary for Fellows, Residents and Students; however registration is required; for instructions on how to receive your complimentary registration you must contact Heidi Brittnacher at 414-805-9427 or [email protected] before attempting to register on-line.
*Please note that this website does not work to its full capacity if using Internet Explorer. Google Chrome and Mozilla Firefox are the preferred browsers.
Target Audience
Physicians and allied health professionals.
Learning Objectives
- Provide an update on the diagnostic work-up of a patient with pancreatic cancer.
- Review multimodality treatment sequencing based on clinical stage for patients with pancreatic cancer.
- Provide an overview of current clinical trials for patients with pancreatic cancer.
- Identification of patients who may be at high risk for developing pancreatic cancer.
VISITING FACULTY
Marina Pasca di Magliano, PhD (University of Michigan)
MCW FACULTY
Susan Tsai, MD, MHS
Michael Griffin, MD, PhD
Beth Erickson, MD
Paul Ritch, MD
Kathleen Christians, MD
Douglas Evans, MD
In accordance with the ACCMEⓇ standard for Commercial Support Number 6, all in control of content have NO relevant financial relationships to disclose with the exception of the following person(s):
Name | Company | Role |
Guari Varadhachary, MD MD Anderson Cancer Center | Celgene Merimack | Strategic Counsil & SAB SAB |
William Hall, MD Medical College of Wisconsin | Elekta | Research support |
Ben George, MD Medical College of Wisconsin | Celgene Cook Medical Foundation Medicine | Consultant Consultant Consultant |
In accordance with the ACCME® standards for Commercial Support Number 6, these relationships were reviewed via the MCW conflict of interest resolution process and resolved.
Available Credit
- 6.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 6.00 Hours of ParticipationHours of Participation credit.